Which has higher valuation & earnings, BWAY or PDEX?

Pro-Dex has higher revenue and earnings than Brainsway. Pro-Dex is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $56.22M 10.87 $7.57M $0.35 43.51 Pro-Dex $66.59M 2.81 $8.98M $3.62 16.18

Is BWAY or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Brainsway's net margin of 15.68%. Pro-Dex's return on equity of 22.78% beat Brainsway's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.68% 12.28% 7.75% Pro-Dex 16.08% 22.78% 14.30%

Which has higher earnings and valuation, PDEX or MDXG?

MiMedx Group has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 2.81 $8.98M $3.62 16.18 MiMedx Group $355.17M 1.73 $48.58M $0.04 103.25

Is PDEX or MDXG more profitable?

Pro-Dex has a net margin of 16.08% compared to MiMedx Group's net margin of 1.76%. Pro-Dex's return on equity of 22.78% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% MiMedx Group 1.76% 11.72% 8.92%

Which has stronger earnings and valuation, PDEX or NPCE?

Pro-Dex has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 2.81 $8.98M $3.62 16.18 NeuroPace $99.53M 4.42 -$21.47M -$0.65 N/A

Is PDEX or NPCE more profitable?

Pro-Dex has a net margin of 16.08% compared to NeuroPace's net margin of -21.67%. Pro-Dex's return on equity of 22.78% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% NeuroPace -21.67% -108.20% -18.50%

Pro-Dex (PDEX) Competitors

$58.57 +1.92 (+3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$58.79 +0.22 (+0.38%)

As of 04:10 PM Eastern

Compare

PDEX vs. SGP, BWAY, MDXG, TCMD, and NPCE

Should you buy Pro-Dex stock or one of its competitors? MarketBeat compares Pro-Dex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pro-Dex include Spyglass Pharma (SGP), Brainsway (BWAY), MiMedx Group (MDXG), Tactile Systems Technology (TCMD), and NeuroPace (NPCE).

How does Pro-Dex compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Pro-Dex has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.18

Pro-Dex has a net margin of 16.08% compared to Spyglass Pharma's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Pro-Dex	16.08%	22.78%	14.30%

15.3% of Pro-Dex shares are held by institutional investors. 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 99.73%. Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 19.52%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Spyglass Pharma had 8 more articles in the media than Pro-Dex. MarketBeat recorded 9 mentions for Spyglass Pharma and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.39 beat Spyglass Pharma's score of 0.35 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyglass Pharma	Neutral
Pro-Dex	Positive

Summary

Pro-Dex beats Spyglass Pharma on 9 of the 13 factors compared between the two stocks.

How does Pro-Dex compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

In the previous week, Brainsway had 6 more articles in the media than Pro-Dex. MarketBeat recorded 7 mentions for Brainsway and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.39 beat Brainsway's score of 0.41 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainsway	Neutral
Pro-Dex	Positive

Brainsway has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Brainsway presently has a consensus target price of $15.67, suggesting a potential upside of 2.87%. Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 19.52%. Given Pro-Dex's higher probable upside, analysts clearly believe Pro-Dex is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

30.1% of Brainsway shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pro-Dex has higher revenue and earnings than Brainsway. Pro-Dex is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$56.22M	10.87	$7.57M	$0.35	43.51
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.18

Pro-Dex has a net margin of 16.08% compared to Brainsway's net margin of 15.68%. Pro-Dex's return on equity of 22.78% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
Pro-Dex	16.08%	22.78%	14.30%

Summary

Pro-Dex beats Brainsway on 9 of the 17 factors compared between the two stocks.

How does Pro-Dex compare to MiMedx Group?

Pro-Dex (NASDAQ:PDEX) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Pro-Dex currently has a consensus target price of $70.00, suggesting a potential upside of 19.52%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 105.81%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, MiMedx Group had 15 more articles in the media than Pro-Dex. MarketBeat recorded 16 mentions for MiMedx Group and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.39 beat MiMedx Group's score of 0.30 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Overall Sentiment
Pro-Dex	Positive
MiMedx Group	Neutral

Pro-Dex has a net margin of 16.08% compared to MiMedx Group's net margin of 1.76%. Pro-Dex's return on equity of 22.78% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
MiMedx Group	1.76%	11.72%	8.92%

Pro-Dex has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MiMedx Group has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.18
MiMedx Group	$355.17M	1.73	$48.58M	$0.04	103.25

Summary

MiMedx Group beats Pro-Dex on 9 of the 16 factors compared between the two stocks.

How does Pro-Dex compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Tactile Systems Technology has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	1.93	$19.09M	$0.88	32.01
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.18

83.4% of Tactile Systems Technology shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 2.1% of Tactile Systems Technology shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pro-Dex has a net margin of 16.08% compared to Tactile Systems Technology's net margin of 5.91%. Pro-Dex's return on equity of 22.78% beat Tactile Systems Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
Pro-Dex	16.08%	22.78%	14.30%

Tactile Systems Technology currently has a consensus price target of $38.60, indicating a potential upside of 37.03%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 19.52%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, equities analysts plainly believe Tactile Systems Technology is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Tactile Systems Technology has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

In the previous week, Tactile Systems Technology had 2 more articles in the media than Pro-Dex. MarketBeat recorded 3 mentions for Tactile Systems Technology and 1 mentions for Pro-Dex. Tactile Systems Technology's average media sentiment score of 1.73 beat Pro-Dex's score of 1.39 indicating that Tactile Systems Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Tactile Systems Technology	Very Positive
Pro-Dex	Positive

Summary

Tactile Systems Technology beats Pro-Dex on 11 of the 17 factors compared between the two stocks.

How does Pro-Dex compare to NeuroPace?

Pro-Dex (NASDAQ:PDEX) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Pro-Dex has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.18
NeuroPace	$99.53M	4.42	-$21.47M	-$0.65	N/A

Pro-Dex has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Comparatively, 19.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pro-Dex presently has a consensus price target of $70.00, suggesting a potential upside of 19.52%. NeuroPace has a consensus price target of $19.29, suggesting a potential upside of 49.62%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts clearly believe NeuroPace is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroPace	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, NeuroPace had 10 more articles in the media than Pro-Dex. MarketBeat recorded 11 mentions for NeuroPace and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.39 beat NeuroPace's score of 0.76 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Overall Sentiment
Pro-Dex	Positive
NeuroPace	Positive

Pro-Dex has a net margin of 16.08% compared to NeuroPace's net margin of -21.67%. Pro-Dex's return on equity of 22.78% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
NeuroPace	-21.67%	-108.20%	-18.50%

Summary

NeuroPace beats Pro-Dex on 9 of the 17 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDEX vs. The Competition

Export

Metric	Pro-Dex	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$186.84M	$5.54B	$6.83B	$12.42B
Dividend Yield	N/A	1.78%	2.59%	10.11%
P/E Ratio	16.18	23.19	281.83	23.65
Price / Sales	2.81	60.60	571.62	79.49
Price / Cash	17.50	32.15	69.88	58.30
Price / Book	5.22	6.32	10.93	5.84
Net Income	$8.98M	$146.99M	$3.49B	$336.16M
7 Day Performance	6.63%	1.82%	-0.32%	0.02%
1 Month Performance	0.03%	6.88%	-2.61%	-5.24%
1 Year Performance	17.02%	1.11%	66.20%	17.34%

Pro-Dex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDEX Pro-Dex	2.747 of 5 stars	$58.57 +3.4%	$70.00 +19.5%	+12.7%	$186.84M	$66.59M	16.18	140	Positive News
SGP Spyglass Pharma	2.5567 of 5 stars	$20.27 +1.2%	$45.00 +122.0%	N/A	$677.69M	N/A	N/A	65	News Coverage Lockup Expiration
BWAY Brainsway	3.9966 of 5 stars	$16.15 -2.1%	$15.67 -3.0%	+159.6%	$662.13M	$56.22M	46.14	120
MDXG MiMedx Group	2.9294 of 5 stars	$4.32 -0.2%	$8.50 +96.8%	-35.0%	$644.93M	$418.63M	21.60	870	News Coverage Earnings Report
TCMD Tactile Systems Technology	4.2566 of 5 stars	$28.43 +0.1%	$38.60 +35.8%	+177.8%	$640.37M	$329.52M	32.31	1,086	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDEX) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pro-Dex (PDEX) Competitors

PDEX vs. SGP, BWAY, MDXG, TCMD, and NPCE

How does Pro-Dex compare to Spyglass Pharma?

Summary

How does Pro-Dex compare to Brainsway?

Summary

How does Pro-Dex compare to MiMedx Group?

Summary

How does Pro-Dex compare to Tactile Systems Technology?

Summary

How does Pro-Dex compare to NeuroPace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pro-Dex (PDEX) Competitors

PDEX vs. SGP, BWAY, MDXG, TCMD, and NPCE

How does Pro-Dex compare to Spyglass Pharma?

Which has stronger valuation and earnings, SGP or PDEX?

Is SGP or PDEX more profitable?

Do insiders and institutionals believe in SGP or PDEX?

Do analysts recommend SGP or PDEX?

Does the media refer more to SGP or PDEX?

Summary

How does Pro-Dex compare to Brainsway?

Does the media favor BWAY or PDEX?

Which has more volatility and risk, BWAY or PDEX?

Do analysts recommend BWAY or PDEX?

Do insiders & institutionals have more ownership in BWAY or PDEX?

Which has higher valuation & earnings, BWAY or PDEX?

Is BWAY or PDEX more profitable?

Summary

How does Pro-Dex compare to MiMedx Group?

Do analysts rate PDEX or MDXG?

Does the media favor PDEX or MDXG?

Is PDEX or MDXG more profitable?

Which has more risk & volatility, PDEX or MDXG?

Do insiders and institutionals have more ownership in PDEX or MDXG?

Which has higher earnings and valuation, PDEX or MDXG?

Summary

How does Pro-Dex compare to Tactile Systems Technology?

Which has stronger earnings & valuation, TCMD or PDEX?

Do institutionals and insiders believe in TCMD or PDEX?

Is TCMD or PDEX more profitable?

Do analysts prefer TCMD or PDEX?

Which has more risk & volatility, TCMD or PDEX?

Does the media prefer TCMD or PDEX?

Summary

How does Pro-Dex compare to NeuroPace?

Which has stronger earnings and valuation, PDEX or NPCE?

Which has more risk and volatility, PDEX or NPCE?

Do institutionals and insiders hold more shares of PDEX or NPCE?

Do analysts rate PDEX or NPCE?

Does the media favor PDEX or NPCE?

Is PDEX or NPCE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools